Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. August 2025 06:30 ET | Quelle: Merakris Therapeutics

Merakris Therapeutics Receives USPTO Notice of Allowance for Foundational Patent Supporting MTX-001 Biologic Drug Platform

RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S....
05. September 2024 06:30 ET | Quelle: Merakris Therapeutics

Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid

Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024.
20. Februar 2024 06:15 ET | Quelle: Merakris Therapeutics

Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid

Merakris to present encouraging Phase 2 clinical drug trial data at annual Treasure Hunt Podiatry and Wound Conference in Los Angeles, CA, February 24-25.
05. Dezember 2023 06:30 ET | Quelle: Merakris Therapeutics

Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial

Merakris Therapeutics announces it has fully enrolled the first part of a clinical trial to evaluate its investigational drug product, Dermacyte® Liquid.